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Departments of Experimental Pathology Â¡E.van 't H., M. J. de V.Â¡,Virology [H. S.], and Hemato/ogy [B. L.], Erasmus University Rotterdam, P. O. Box 1738,
Rotterdam, The Netherlands
ABSTRACT
The toxicity of Interferon to bone marrow was studied
by the use of in vitro colony forming assays for hemo-
poietic cells. In the same study the relative inhibitory
effects of two clinically common Interferon preparations,
leukocyte and fibroblast interferons, were compared with
regard to their effect on both myeloid [colony-forming
unit, culture (CPU,)] and erythroid [colony-forming unit,
erythroid (CPU,)] progenitor cells. CPU, formation in hu
man bone marrow cells in vitro appeared to be fairly
resistant to both interferons. Only high doses of both
interferons gave a marked inhibition of CPU,,.
However, the toxicity of leukocyte and fibroblast Inter
feron was divergent for CPU, in human bone marrow.
Leukocyte Interferon appeared to be considerably more
inhibitory for CPU, than was fibroblast Interferon.
The effects of mouse Interferon, induced in L929 cells,
on the growth of CPU, and CPU, in murine bone marrow
cells were comparable with those of fibroblast Interferon
on human cells.
The toxicity of human and murine Interferon was spe
cies specific. Except for the toxicity of leukocyte inter-
feron to CPU,, in human bone marrow, the toxicity of
Interferon was marked only with concentrations of Inter
feron far exceeding the amount necessary to produce an
antiviral state in vitro.
INTRODUCTION
Viral infections present a major problem in primates
(rhesus monkey and human patients) with primary immune
deficiencies and those subjected to immunosuppressive
therapy. It has become evident that the seventy and inci
dence of viral infections are particularly prominent in pa
tients who have been treated with immunosuppressive
regimens following allogeneic bone marrow transplants (2,
19). The further development of bone marrow transplanta
tion in humans is largely dependent on the possibility for
control or prevention of these complications (18). Recently,
the successful application of Interferon as an anti-viral drug
in humans was reported (7, 9, 11).
Interferon preparations in high concentrations, however,
inhibit cell division. Therefore one must be aware of possi
ble bone marrow toxicity (6) because, particularly in pa
tients treated with bone marrow transplantation and in
patients treated with cytotoxic agents, the bone marrow
reserve may be severely limited. Testing of the clinically
applied interferon preparations for bone marrow toxicity
prior to clinical use will be important. This can hardly be
achieved in vivo in man. Therefore one must rely on in vitro
assays that determine the proliferative capacity of hemo-
poietic cells. Colony-forming cultures, in which progenitor
cells are induced to proliferate and differentiate towards
clones of daughter cells, may meet the criteria of a conven
ient assay in this respect.
Human leukocyte interferon and human fibroblast inter
feron and their effects on hemopoietic myeloid and ery
throid progenitors in culture were studied. The inhibition of
the formation of granulocytic-macrophage colonies and
erythroid colonies during exposure of marrow cells to
interferon was investigated. The effect of mouse L-cell
interferon on the formation of erythroid as well as granulo-
cytic colonies in mouse bone marrow was also included in
the study in order to compare the species specificity of all
tested interferon preparations.
MATERIALS AND METHODS
Interferon Preparations
Human Interferon. Partially purified leukocyte interferon
was kindly supplied by Dr. Cantell, Helsinki, Finland.
The interferon was induced and semipurified as de
scribed before (5). The leukocyte interferon batch used had
an activity of 6 x 106 IRUVml and a protein concentration
of 7 mg/ml.
Human fibroblast interferon was kindly supplied by Dr. V.
G. Edy, Leuven, Belgium.
The interferon was induced and semipurified as de
scribed before (3) and had a specific activity of 106 IRU/20
mg of protein. A control preparation was prepared from
human plasma protein Fraction V, following the same
procedures as used for the manufacture of the interferon
preparations. This preparation was also used as a control
in in vivo studies in patients.
Mouse Interferon. Mouse interferon was induced with
Newcastle disease virus in mouse L929 cells and prepared
as described before (1).
The interferon had a specific activity of 106 IRU/mg of
protein. Control preparations were prepared from normal
L929 cell supernatant following the same procedures as
those used to prepare the interferon preparations.
The interferon preparations were diluted to the desired
concentration in Dulbecco's MEM and were added to the
cell suspensions as a part of the culture medium wherein
the cells were cultured.
Received August 26. 1977; accepted January 11, 1978.
1The abbreviations used are: IRU, International reference unit; MEM,
minimal essential medium; CFUr, colony-forming unit, culture; CPU,, colony-
forming unit, erythroid.
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Preparations of Cells
Human bone marrow was obtained aseptically from pa
tients requiring a diagnostic puncture. Patients were suffer
ing from a variety of diseases, predominantly malignant
tumors and infections; some patients manifested a mild
anemia. Human blood was collected by venipuncture. The
erythrocytes were removed from the nucleated marrow and
blood cells by sedimentation at unit gravity in 0.1% methyl
cellulose (Methocel McDow Chemical Co., Midland, Mich.)in Dulbecco's MEM (Flow Laboratories, Irvine, Ayrshire,
Scotland).
Mouse bone marrow was obtained by dissecting the
femurs of 6- to 8-week-old female BALB/c mice. One of the
ends was cut with scissors, and the marrow was flushedfrom the shafts. All cells were carefully washed with Hanks'
balanced salt solution after collection.
Myeloid Colony Cultures for Human Cells
To determine the number of CFU,, we adopted the culture
method of Pike and Robinson (17).
The underlayers were prepared by mixing 106 leukocytes
with 1 ml of culture medium (0.5% agar, 20% serum, andDulbecco's MEM (Flow Laboratories). The serum compo
nent contained equal parts of horse serum, fetal calf serum,
and 3% Trypticase Soy Broth (Difco Laboratories, Detroit,
Mich.). Thereafter, an overlayer containing the marrow cellsin 0.25% agar in Dulbecco's MEM, supplemented with 20%
serum, was pipeted on top of the leukocyte underlayers.
After 14 days of incubation in a humidified atmosphere of
5% CO2-95%air, the colonies were counted with an inverted
microscope.
Three Petri dishes were used for each experimental point.
Erythroid Colony Cultures from Human Cells.
Colony formation in plasma clots was determined accord
ing to the method of McLeod ef al. (13). Nucleated bone
marrow cells in a concentration of 2 x 103/ml were sus
pended in medium containing Dulbecco's MEM, 20% fetal
calf serum, 1% bovine albumin (Fraction V; Sigma Chemical
Co., St. Louis, Mo.), 2% asparagine, 0.25 unit erythropro-
tein (Step III; Connaught Medical Laboratories, Willowdale,
Ontario, Canada), and 10% bovine citrated plasma (Grand
Island Biological Co., Grand Island, N. Y.). The cells were
cultured in microtiter plates (C. A. Greiner und SÃ¶hne,
D-7440 NÃ¼rtingen,Germany), and 0.1 ml of the cell suspen
sion was incubated per well.
The cultures were placed in an incubator under the same
conditions as those used for the myeloid colony method.
After 2.5 days of incubation, the clots were removed from
the microtiter plates and stained with benzidine after fixa
tion with 5% glutaraldehyde in phosphate-buffered saline
(0.01 M isotonic Na-HPOrKH.PO, buffer, pH 7.0 to 7.2).
Cell aggregates containing more than 8 cells were
counted with the light microscope. The aggregates con
sisted of differentiated erythroblasts. Each experimental
point represents the average colony counts of at least 10
whole clots.
Granulocytic-Macrophage Colony Cultures of Mouse Cells
The system was originally described by Bradly and Met-
calf (4). Nucleated bone marrow cells were suspended in an
agar solution (0.3%) in Dulbecco's MEM supplemented with
20% serum (consisting of equal parts of horse serum, fetal
calf serum, and 3% Trypticase Soy Broth solution).
One ml of this mixture containing 105cells was plated per
plastic Petri dish (diameter, 3.5 cm). As a stimulator 0.1 ml
of mouse fibroblast-conditioned medium was added to
each plate. The dishes were incubated for 6 days under the
same conditions as those for the other cultures. Thereafter,
colonies were counted.
RESULTS
Human leukocyte and human fibroblast interferons, when
added to the culture, inhibit human CFU,.. The extent of
inhibition is linearly related to the dosage of Interferon
(Chart 1). Human leukocyte and human fibroblast interferon
preparations also suppress the formation of granulocyte-
macrophage colonies (CFU,) (Chart 2). The degree of inhi
bition of CFU,. and CFU, by human fibroblast interferon is
approximately equivalent. Colony growth from both cell
populations appears to be reduced by approximately 50%
in the presence of 10" IRU/ml.
Hum Fibroblast IF
â€¢Hum Leucocyte I F
\ I
100
i\
10 10 10' 10' i.RU. IF./â€ž,
Chart 1. Cytotoxicity of human (Hum.) leukocyte and human fibroblast
Interferon (IF) for human CFU, Nine experiments: oars. S.D.
100
o
cÂ«
Hum Fibroblast IF
â€¢Hum Leucocyte IF
10 10 10 10
Chart 2. Cytotoxicity of human (Hum.) leukocyte and human fibroblast
interferon (IF) lor human of CFU, Nine experiments; oars, S.D.
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Table 1
Specificity of the toxicity of Interferon preparations
CPU,, and CFUe of mouse bone marrow cells"
Human fibroblast interferon Human leukocyte interferon
Control1
x 104 IRU
1 x 103 IRU
1 x 10* IRU
1 x 10 IRU
Mock interferonCFUe/105
cells202.3
Â±24.7*
194.7 Â±23.7
203.4 Â±26.6
209.9 Â±24.4
198.7 Â±26.6
197.1 Â±20.1CFUC/10S
cells100.0
Â±10.0
94.4 Â± 7.4
98.6 Â±11.4
101 .5 Â± 7.4
99.6 Â±11.3
102.4 Â± 8.2CFUe/105
cells202.3
Â±24.7
131.3 Â±20.1
177.1 Â±25.9
191.2 Â±21.9
208.3 Â±35.5CFUC/105
cells100.0
Â±10.0
58.8 Â± 9.6
91.5 Â± 9.1
102.9 Â±10.4
102.7 Â±10.3
" Human bone marrow cells were not inhibited by mouse L-cell interferon preparations.
6 Mean Â±S.D.
However, human leukocyte interferon diverges clearly
from fibroblast interferon: (a) it is significantly more toxic
to human CPU,,than to CPU,.; (o) this interferon shows no
or only a minor inhibitive effect on murine CFU,. and CPU,.
(Table 1).
A third interferon preparation, produced in mouse L929
cells, was also investigated for its effect on human and
mouse progenitor cells. Whereas mouse interferon shows
inhibition of the colony growth of mouse CPU,,and CPU,,in
a linear dose-effect relationship (Charts 3 and 4), it is not
toxic for human bone marrow (results not shown).
This indicates that the toxicity of human interferon may
be species dependent.
DISCUSSION
Interferon preparations inhibit CPU,, and CFUC.in vitro.
Human fibroblast interferon inhibits the formation of CPU,,
and CPU,,in vitro at concentrations much larger than those
needed for the establishment of the antiviral state of cells in
vitro. The toxic concentration of fibroblast interferon also
exceeds the serum titer of interferon in patients treated with
high doses of fibroblast interferon [20 x 106 IRU/ml fibro
blast interferon daily, a serum titer rise of 30 IRU/ml (V. G.
Edy, personal communication)]. The effect of leukocyte
interferon on CFU\, is similar to that of human fibroblast
interferon, but human leukocyte interferon is comparatively
more toxic to CPU,.. Only 10 units leukocyte interferon
suffice to inhibit the growth of CPU, by approximately 40%,
whereas as much as 10* units of fibroblast interferon are
needed to produce a similar reduction. Using a similar
assay system, other investigators have reported that human
leukocyte interferon preparations may be extremely toxic
for granulocyte-macrophage colonies in human bone mar
row cultures (10, 16). To our knowledge the effect on
erythroid progenitors has never been investigated.
Others have demonstrated in a different experimental
system that the cytotoxic and antiviral activities of inter
feron preparations share many physicochemical and bio
logical characteristics (12, 15). This may suggest that inter
feron itself is responsible for the cytotoxic effects. However,
in view of the nonavailability of completely purified inter
feron, one cannot be certain whether the cytotoxicity is due
to impurities in the preparation. Comparison of the cyto
toxic effect of human leukocyte interferon on mouse and
human CPU,.,respectively, shows that this interferon is less
toxic for mouse bone marrow, indicating a (cell- and spe-
100
3
U-.
U
I
10 io2 io3 10" l R.U. IF/ml
Chart 3. Cytotoxicity ot mouse L-cell inferieron (IF) for mouse CFU,. Five
experiments; bars, S.D.
100
D
U
I
I
IÂ£
10 10' 10 10 l R U IF /m|
Chart 4. Cytotoxicity of mouse L-cell interferon (IF) for mouse CFU,. Five
experiments; oars, S.D.
cies-) specific effect and not toxicity due to impurities.
Therefore the cytotoxic effect could be closely related to
the antiviral effect of interferon (compare Chart 2 and Table
1).
The toxicity of leukocyte Â¡nterferoncould pose a problem
in clinical application because it is already apparent at
lower than pharmacological concentrations.
The finding that leukocyte interferon is more toxic for
CPU,,than for CPU,,is of interest in view of previous work of
Einhorn ef al. (8). They suggest that the inhibiting effects of
interferon are specific for those target cells that are preva
lent in the tissue in which the interferon is induced.
The effect of mouse interferon on murine CPU,,and CPU,
is essentially similar to that of human fibroblast interferon
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on human bone marrow. The adverse effect of L-cell inter-
feron on the colony formation has been reported to be less
prominent than the effect of interferons from other murine
sources. McNeill (14) explained this effect by a contamina
tion of L-cell interferon with colony-stimulating activity, but
in our material no significant colony-stimulating activity
was present.
No doubt, it will be necessary in the future to test the
interferon toxicity on bone marrow for in vivo relevance.
This should be done in direct comparison with clinical and
hematological parameters, and this should finally establish
the value of the method. Until the toxicity ratio of interferon
has been more thoroughly established in in vivo studies,
one must rely largely on extrapolation from in vitro tests.
The above data imply that, in terms of marrow toxicity,
human fibroblast interferon might represent a preferable
choice over leukocyte interferon, especially in patients with
a marrow insufficiency.
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